PDCD1 and neoplasm: However, the increased anti-tumour immune response with combined anti-LAG-3 and anti-PD-1 therapies comes with the cost of higher immune-related adverse events (irAEs), with 21.1% of patients on combination therapy experiencing grade 3 or 4 events compared to 11.1% with anti-PD-1 monotherapy [21].